Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 6;13:955925. doi: 10.3389/fphar.2022.955925

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Jian, Zhan, Hu, He, Chen, Hu and Lu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of systemic triplet therapy for improving OS. (A) Forest plot representing HR for each therapy compared with ADT plus docetaxel. HR and 95% CrI are represented. (B) SUCRA plot showing the treatment ranking of therapies. (C) League table of network meta-analysis comparing the OS effects of systemic therapies. Comparison is located at the intersection of the column-defining treatment and the row-defining treatment. The results are presented in HR with 95% CrI. HR>1 (red color) favors row-defining treatment, and HR<1 (green color) favors column-defining treatment. Dark red or green color represents the results with statistical significance. ADT, androgen deprivation therapy; SNA, Standard nonsteroidal antiandrogen; DO,: Docetaxel; ABI, Abiraterone, ENZA, Enzalutamide; DARO, Darolutamide; APA, Apalutamide.